Dr. Susan Sobolov, Chief Operating Officer at Caelum Biosciences, is a biopharmaceutical executive and a proven RD leader with a passion for delivering transformative drugs for patients. She has over 23 years of experience across all drug development lifecycle in companies ranging from large caps (Pfizer and Novartis NIBR) to smaller public and private biotech companies (Caelum, Alexion, Fortress Biotech).
She is skilled at communicating complex concepts to diverse audiences and is widely known and respected for uncompromising personal ethics and professional integrity.
She is a board member for Children’s house, Board of Education for Essex. CT, Founding CT Chapter Chair of Women in BIO, Scientific and Consumer Advisor for the Congressionally DOD Directed Medical Research Programs.
She has over 33 patents, 20 publications, and she is an active Industry Speaker.
Susan has a B.S in Chemistry from the University of Vermont, a Professional Program in Finance, Leadership, and Global Project Management from MIT, a Ph.D. in Synthetic Organic Chemistry from Yale University, and a post-Doctoral fellowship from Harvard University.
She is skilled at communicating complex concepts to diverse audiences and is widely known and respected for uncompromising personal ethics and professional integrity.
She is a board member for Children’s house, Board of Education for Essex. CT, Founding CT Chapter Chair of Women in BIO, Scientific and Consumer Advisor for the Congressionally DOD Directed Medical Research Programs.
She has over 33 patents, 20 publications, and she is an active Industry Speaker.
Susan has a B.S in Chemistry from the University of Vermont, a Professional Program in Finance, Leadership, and Global Project Management from MIT, a Ph.D. in Synthetic Organic Chemistry from Yale University, and a post-Doctoral fellowship from Harvard University.
Activity